Jun 30, 2023 / 12:00PM GMT
Operator
Good day, and welcome to the GENFIT Positive Top Line Data from Phase III ELATIVE trial of elafibranor in patients with Primary Biliary Cholangitis conference call. Today's call will be recorded.
At this time, I'd like to turn the call over to Stefanie Magner. Please go ahead.
Stefanie Magner - Genfit S.A. - Chief Compliance Officer & Executive VP of International Legal Affairs
Hello, everyone, and thanks for joining us on this conference call organized to follow up on the press release we published with Ipsen today on the elafibranor Phase III ELATIVE trial results. The press release can be accessed via our website at ir.genfit.com.
Joining me on the call today are Pascal Prigent, CEO; and Carol Addy, CMO.
Before we begin, I'd like to remind everyone that statements made during this conference call relating to the group's expected future performance, market potential business prospects, events or plans, including clinical plans, potential to obtain regulatory approvals, anticipated time lines for clinical development and study
Genfit SA and Ipsen SA Announce Positive Results from Phase III ELATIVEĀ® Trial of Elafibranor in Patients with Primary Biliary Cholangitis Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot